The impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the mortality in sepsis: A systematic review and meta-analysis

Yi Yu (✉ 1191922959@qq.com)
Guangdong Hospital of Traditional Chinese Medicine

Jing Huang
Guangdong Hospital of Traditional Chinese Medicine

Bojun Zheng
Guangdong Hospital of Traditional Chinese Medicine

Jian Zhang
Guangdong Hospital of Traditional Chinese Medicine

Jian Li
Guangdong Hospital of Traditional Chinese Medicine

Research

Keywords: sepsis, mortality, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, systematic review

Posted Date: January 15th, 2020

DOI: https://doi.org/10.21203/rs.2.20958/v1

License: ☒  This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The effect of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on the mortality of patients with sepsis is not well characterized. The aim of this study was to elucidate the association between prior ACEI or ARB exposure and mortality in sepsis.

Methods

The PubMed, Embase, Web of Science, and Cochrane Library databases were searched for all studies of premorbid ACEI or ARB use and sepsis mortality until November 30 2019. Two reviewers independently assessed, selected, and abstracted data from studies reporting ACEIs or ARBs, sepsis, and mortality. The primary extracted data consisted of premorbid ACEI or ARB exposure, mortality, and general patient data. Two reviewers independently assessed the risk of bias and quality of evidence.

Results

A total of six studies comprising 281,238 patients with sepsis, including 49,799 cases with premorbid ACEI or ARB exposure were eligible for analysis. Premorbid ACEIs or ARBs exposure decreased the 30-day mortality in patients with sepsis. Moreover, the use of ACEIs or ARBs was associated with approximately a 6% decreased risk of 30-day mortality.

Conclusions

The results of this systematic review suggest that ACEI or ARB exposure prior to sepsis may be associated with reduced mortality. Further high-quality cohort studies and molecular mechanism experiments are required to confirm our results.

Background

Sepsis is a syndrome that involves physiological, pathological, and biochemical abnormalities resulting from a host response to an infection, and represents a major public health concern[1]. Sepsis is a "worldwide medical problem" that endangers human health and is associated with three main characteristics: 1) high incidence; 2) high mortality; and 3) high treatment cost. More than 19 million people suffer from sepsis every year worldwide, with a fatality rate greater than 25% [2].

As sepsis progresses after an infection, an imbalance of the pro-inflammatory and anti-inflammatory response develops [3]. The guidelines associated with development of the sepsis pathophysiology suggest: early fluid resuscitation, antibiotic treatment, control of infection sources, use of vasoactive agents, corticosteroids, blood products, immunoglobulins, blood purification as treatment options [4]. Although the guidelines for the diagnosis and treatment of sepsis have been revised several times, the monitoring index does not fully reflect the overall situation and dynamic changes of the patients,
treatment is associated with a lag period, and the mortality rate remains high [5]. Therefore, it is important to accurately identify potential patients who are at a high risk of sepsis and to take specific intervention measures to reduce the mortality of such patients. Such supplement to the previous treatment programs and may improve the prognosis of sepsis patients.

Several studies have suggested that the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may represent a therapeutic option for patients with sepsis [5]. Moreover, ACEIs and ARBs have been shown to exert anti-inflammatory effects to attenuate the chronic inflammation [8]. However, the benefit of using ACE inhibitors or ARBs remains controversial [9, 10]. Moreover, there are no published systematic reviews on the effects of premorbid ACEI or ARB exposure on sepsis mortality. Thus, this study sought to investigate sepsis mortality in patients with prior ACEI and ARB exposure.

**Materials And Methods**

**Search strategy**

This study followed the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines [11]. A literature search of relevant published studies that analyzed the association between the sepsis, mortality, and ACEIs or ABBs was conducted on November 30 2019. We used the PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), Embase (http://www.embase.com/), Web of Science (http://wokinfo.com/), and Cochrane Library (http://www.thecochranelibrary.com/) databases to identify articles using the following terms: “hypotensor”; “antihypertensive”; “ACEIs”; “ARBs”; “sepsis”; “sepsis shock”; and “mortality”. In addition, the reference lists in each of the studies were reviewed to identify additional studies. The language of the studies was limited to English, and we did not search for unpublished literature.

**Study selection criteria**

A study was included in the analysis if: 1) it a case-control or cohort study was conducted; 2) it was an original human clinical trial (independence among studies) that evaluated the association between premorbid ACEI or ARB exposure and sepsis mortality; and 3) it provided sufficient data (e.g., to calculate the relative risk [RR], odds ratio [OR], or hazard ratio [HR]); and 4) the (Newcastle-Ottawa Scale, NOS) score value was ≥ 5. We excluded studies that contained overlapping data.

**Data extraction**

The data extracted from the selected articles included: the first author’s name; year of publication; study population; total number of cases; RRs or ORs with 95% confidence intervals (CIs); Newcastle-Ottawa Scale (NOS); and adjustments made in the studies (Table 1). Some publications separate reported ORs
for ACEI-related sepsis mortality and ARB-related sepsis mortality. In these cases, the ORs were separately extracted.
Table 1
Characteristics of the studies included in the meta-analysis

| Study          | Year | Population and country | No. of cases | Study type   | Adjustment OR (95% CI) | Adjustment                                      | NOS |
|----------------|------|------------------------|--------------|--------------|------------------------|-------------------------------------------------|-----|
| Mortensen EM et al. | 2007 | 3,018 USA              | 547          | Cohort       | ARBs: 0.42 (0.24–0.76) | Age, history of myocardial infarction, heart failure, stroke, peripheral vascular disease, chronic lung disease, dementia, and moderate liver disease | 6   |
| Dial S et al.     | 2014 | 21,615 UK              | 1,965        | Cohort       | ACEIs: 1.93 (1.56–2.40) | Age, gender, BMI, ever smoking, blood pressure, alcohol abuse, comorbidity, medication | 7   |
| Wiewel MA et al. | 2017 | 6,994 Netherlands      | 1,483        | Cohort       | ACEIs/ARBs: 1.27(0.88–1.84) | Age, gender, Acute Physiology and Chronic Health Evaluation IV score, race, weight, comorbidity and medication | 7   |
| Hsieh MS et al.  | 2019 | 223,560 Taiwan, China  | 33,213       | Cohort       | ACEIs: 0.93(0.88–0.98) | Age, gender, insurance premium, urbanization level and comorbidity. | 6   |
| Kim J et al.     | 2019 | 4,549 South Korea      | 673          | Cohort       | ACEIs/ARBs: 1.32(1.11–1.56) | Age, gender, comorbidity (heart failure, ischemic heart disease, asthma, chronic renal disease, diabetes, cerebrovascular disease, and solid tumor). | 7   |

No., number; CI, confidence interval; OR, odds ratio; NOS, Newcastle-Ottawa Scale; BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker
| Study       | Year   | Population and country | No. of cases | Study type | Adjustment OR (95% CI) | Adjustment                | NOS |
|------------|--------|------------------------|--------------|------------|------------------------|----------------------------|-----|
| Lai CC et al. | 2019   | 21,502 Taiwan, China   | 11,918       | Cohort     | ACEIs/ARBs: 1.31(1.22–1.40) | Age, gender, comorbidities, medication. | 7   |

No., number; CI, confidence interval; OR, odds ratio; NOS, Newcastle-Ottawa Scale; BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker

### Statistical analysis

The strength of the association between premorbid ACEI or ARB exposure and susceptibility to sepsis mortality was reported using ORs and 95% CIs. ACEIs or ARBs were defined as captopril, enalapril, benazepril, fosinopril, ramipril, losartan, valsartan, and candesartan. When the data was adjusted and crude ORs were provided, the most adjusted ORs were extracted. If the article provided an HR, it was converted to an OR using the appropriate formula [12]. We used an $I^2$ test and Q-statistic to detect any possible heterogeneity between the studies, as a quantitative measure of any inconsistencies among the studies[13]. In addition, we clarified the percentage of the total variation across the studies that was due to heterogeneity rather than by chance using the $I^2$-statistic. Pooled ORs and 95% CIs were calculated using a random-effects model [14].

All statistical analyses for the meta-analysis were performed using STATA version 12.0 (USA, College Station, TX 77845). Statistical significance was established at a threshold of $P \leq 0.05$. All reported $P$ values were obtained from two-sided statistical tests. Egger's and Begger's regression models were used to evaluate the potential publication bias[14].

### Results

The process used to select the studies for analysis is outlined in Fig. 1. A total of 118 potentially relevant records were reviewed, of which six articles, which included 49,799 cases that met the inclusion criteria were included in the meta-analysis [15–20] (Table 1). A total of 112 studies were subsequently excluded because they used a combined intervention, were duplicated reports, or were of relatively low quality. All of the six selected articles were cohort studies.

Three studies were conducted in Asia and three studies were conducted in other regions (Europe and America). Two studies presented the mortality separately for ACEIs and ARBs. The NOS was 7 and 6 in four and two studies, respectively (Table 2). The mortality data for both ACEIs and ARBs were individually extracted. The results from the six studies were inconsistent: two studies reported that premorbid ACEI or ARB use was associated with a significant reduction in sepsis mortality, whereas the other four studies reported no association. The analysis of the six studies yielded a combined risk estimate of (OR: 0.94;
95% CI: 0.91–0.97; \( P = 0.001 \)) with a heterogeneity value (\( I^2 \)) of 94.6% for 30-day mortality (Fig. 2). We conducted a meta-regulation test and found that the geographical area was associated with 25.49% reduction in heterogeneity across the six studies (Figs. 3 and 4). We further evaluated the role of (ACEIs, ARBs, and ACEIs/ARBs) in a meta-regulation test, which was associated with a 35.13% reduction in heterogeneity across the six studies.

We conducted a meta-regulation test and found that the geographical area was associated with 25.49% reduction in heterogeneity across the six studies (Figs. 3 and 4). We further evaluated the role of (ACEIs, ARBs, and ACEIs/ARBs) in a meta-regulation test, which was associated with a 35.13% reduction in heterogeneity across the six studies.

| Group          | No. of studies | OR (95% CI)          | \( P \) heterogeneity | \( I^2 \) (%) |
|---------------|---------------|----------------------|------------------------|--------------|
| Geographic area |               |                      |                        |              |
| Non-Asia      | 4             | 0.91 (0.74–1.09)     | 0                      | 94.6         |
| Asia          | 4             | 0.94 (0.91–0.98)     | 0                      | 96.7         |
| Object        |               |                      |                        |              |
| ACEIs         | 2             | 0.94 (0.89–0.99)     | < 0.01                 | 95.3         |
| ARBs          | 3             | 0.84 (0.79–0.88)     | 0.006                  | 80.7         |
| ACEIs/ARBs    | 3             | 1.31 (1.23–1.39)     | 0.983                  | 0            |
| NOS           |               |                      |                        |              |
| 6             | 3             | 0.88 (0.85–0.91)     | 0                      | 88.6         |
| 7             | 5             | 1.31 (1.24–1.39)     | 0.013                  | 68.4         |

Due to differences in the geographic area (Asian or non-Asian countries), NOS (7 or 6), and prior exposure (ACEIs, ARBs, and ACEIs/ARBs) between the studies, we conducted further subgroup analyses to determine the effect of these factors in our analyses (Table 2). We obtained a statistically protective effect in Asian population (OR: 0.94; 95% CI: 0.91–0.98), ACEIs (OR: 0.94, 95% CI: 0.89–0.99), ARBs (OR: 0.84, 95% CI: 0.79–0.88), NOS of 6 (OR: 0.88; 95% CI: 0.85–0.91), in a non-Asian population (OR: 0.91; 95% CI: 0.74–1.09), NOS of 7 (OR: 1.31; 95% CI: 1.24–1.39), and ACEIs/ARBs (OR: 1.31; 95% CI: 1.23–1.39).

Based on Egger's and Begger's regression models (23), there was no evidence of publication bias (Figs. 5 and 6) regarding prior ACEI or ARB exposure and mortality in sepsis. The Egger's funnel plot revealed a \( P \) value > 0.05 and Begger linear regression test (\( P > 0.05 \)).

**Discussion**
This is the first systematic review examining the role of premorbid ACEI or ARB exposure on mortality outcomes in patients with sepsis. Patients receiving ACEIs or ARBs prior to developing sepsis were associated with a 6% reduction in 30-day mortality compared with those who did not receive any ACEIs or ARBs. We further conducted subgroup analyses to determine the effect of the geographic area (Asian or non-Asian countries), NOS (7 or 6), and prior exposure (ACEIs, ARBs, and ACEIs/ARBs) in our analyses (Table 2). We obtained a statistically protective effect in the Asian population (OR: 0.94; 95% CI: 0.91–0.98), ACEIs (OR: 0.94; 95% CI: 0.89–0.99), ARBs (OR: 0.84; 95% CI: 0.79–0.88), and a NOS of 6 (OR: 0.88; 95% CI: 0.85–0.91). The results of a meta-regulation test (Figs. 3 and 4) revealed that the geographical area and treatment were associated with 60.62% reduction in heterogeneity across the studies.

One cause of the differences in the outcomes between population may be lifestyle and environmental factors associated with Asian and non-Asian populations [21–23]. Compared with European and American populations, Asian populations have a relatively healthy diet and a lower prevalence of chronic diseases (e.g., diabetes and coronary heart disease) [21–23], which have a substantial impact on the prognosis of sepsis.

ACE inhibitors and ARBs reduce blood pressure by vasodilation, decreasing angiotensin II formation, and kallikrein degradation to reduce sodium and water retention [27]. These effects can also decrease the glomerular filtration rate (GFR) since angiotensin II plays a critical role in the maintenance of GFR, especially during hypovolemia or hypotension [28, 29]. In the guidelines for sepsis treatment, the maintenance of a certain tissue perfusion pressure is necessary; however, the use of ACE inhibitors and ARBs appear to be contrary to the recommended treatment guidelines for sepsis. Moreover, ACE inhibitors and ARBs have not been recommended as a therapeutic drug in previous septic diagnosis and treatment guidelines. In addition to the effect of lowering blood pressure, both ACE inhibitors and ARBs also have anti-inflammatory effects, which can reduce plasma cytokine and nitric oxide concentrations [28, 29]. In septic animal models, although ACE inhibitors have been demonstrated to reduce organ damage through the NF-κB signaling pathway [31], conflicting data exist regarding to whether an angiotensin II blockade improves survival in animal models [32, 33]. Moreover, a clinical study of patients hospitalized with sepsis reported that the prior use of ARBs was associated with improved survival [34].

Our findings have potential clinical implications. Clinical medical providers should be able to identify who is at a high-risk of sepsis as early as possible and guide the course of treatment following the initial screening. Combined with our meta-analysis, the use of ACEIs or ARBs can improve the prognosis of sepsis patients, and the comparison of the effect of ACEIs and ARBs on the prognosis of sepsis is presently not supported by any data. Therefore, if patients treated with ACEIs cannot tolerate their adverse reactions, they can continue to use ARBs. It is recommended that ACEIs or ARBs be abandoned only if the adverse effects are severely intolerable [35, 36].

This study analyzed data from six observational studies and included a larger population and range of trials compared to that previous studies, with the largest number of cases analyzed to date. We conformed to the specifications throughout the entire meta-analysis process and we also simultaneously
conducted a publication bias detection. The obtained results are robust and the included analysis was free from obvious publication bias. Moreover, this meta-analysis has a high standard for the quality of the included literature, and thus meets a high quality standard.

There are a few limitations regarding this study that should be noted. First, when selecting appropriate literature, only studies written in English were included; however, a large portion of the articles that were included in our study were performed in Asia, where the official language is not English. Second, it was challenging to predict the effect of misclassification of cohort studies for the results. In addition, the systematic confounding or the risk of bias cannot easily be ruled out in observation studies. Since there was heterogeneity across the studies, we performed a regression analysis to explain the source of such heterogeneity. The observed differences may be due to the differences in the geographical area of the studies. Specifically, differences in the study geographical area and prior treatment (ACEIs, ARBs, and ACEIs/ARBs) may have contributed to the heterogeneity observed in our results (Fig. 4). In this analysis, the comparison between the dose and course of treatment of ACEIs or ARBs and the prognosis of sepsis were not included due to the lack of data provided in the original studies.

**Conclusion**

In summary, the findings of this systematic review suggests that exposure to ACEIs or ARBs prior to an episode of sepsis could have a role in reducing sepsis mortality; however, additional evidence is required to clarify whether premorbid ACEIs or ARBs can reduce sepsis mortality, as well as the associated mechanism. Therefore, further high-quality cohort studies and molecular mechanism experiments are required to confirm our results.

**Declarations**

**Acknowledgements**

We would like to thank the native English speaking scientists of Elixigen Company (Huntington Beach, California) for editing our manuscript.

**Authors’ contributions**

Jian Li and Jian Zhang designed the study. Yi Yu and Jing Huang conducted the literature search and data analysis. Bojun Zheng drafted the manuscript. Yi Yu, Jing Huang and Jian Zhang revised the manuscript. All authors read and approved the final manuscript.

**Funding**

The Special Science and Technology Research of Guangdong Provincial Hospital of Traditional Chinese Medicine (No. YN 2014 PJR 203), the Guangdong Provincial Bureau of Traditional Chinese Medicine
(grant number, 20181117) and the Guangdong Provincial Key Laboratory of Research on Emergency in TCM (grant number, 2017B030314176).

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Ethics approval for systematic review is not required.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Torio CM, Andrews RM: National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011: Statistical Brief #160. 2006.

2. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016, 315(8):801-810.

3. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG: The immunopathology of sepsis and potential therapeutic targets. *NAT REV IMMUNOL* 2017, 17(7):407-420.

4. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016, 315(8):801-810.

5. Iwashyna TJ, Ely EW, Smith DM, Langa KM: Long-term cognitive impairment and functional disability among survivors of severe sepsis. *JAMA* 2010, 304(16):1787-1794.

6. Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A, Good C, Restrepo MI, Downs JR, Frei CR et al: Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. *CLIN INFECT DIS* 2012, 55(11):1466-1473.

7. Dial S, Nessim SJ, Kezouh A, Benisty J, Suissa S: Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis. *Br J Clin Pharmacol* 2014, 78(5):1151-1158.

8. Podowski M, Calvi C, Metzger S, Misono K, Poonyagariyagorn H, Lopez-Mercado A, Ku T, Lauer T, McGrath-Morrow S, Berger A et al: Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. *J CLIN INVEST* 2012, 122(1):229-240.
9. Dial S, Nessim SJ, Kezouh A, Benisty J, Suissa S: Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis. *Br J Clin Pharmacol* 2014, 78(5):1151-1158.

10. Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A, Cornell JE, Pugh MJ: Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. *PHARMACOTHERAPY* 2007, 27(12):1619-1626.

11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. *Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA* 2000, 283(15):2008-2012.

12. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. *TRIALS* 2007, 8:16.

13. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. *BIOMETRICS* 1994, 50(4):1088-1101.

14. DerSimonian R, Laird N: Meta-analysis in clinical trials revisited. *CONTEMP CLIN TRIALS* 2015, 45(Pt A):139-145.

15. Hsieh MS, How CK, Hsieh VC, Chen PC: Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs). *SHOCK* 2019.

16. Kim J, Kim YA, Hwangbo B, Kim MJ, Cho H, Hwangbo Y, Lee ES: Effect of Antihypertensive Medications on Sepsis-Related Outcomes: A Population-Based Cohort Study. *CRIT CARE MED* 2019, 47(5):e386-e393.

17. Lai CC, Wang YH, Wang CY, Wang HC, Yu CJ, Chen L: Risk of Sepsis and Mortality Among Patients With Chronic Obstructive Pulmonary Disease Treated With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. *CRIT CARE MED* 2019, 47(1):e14-e20.

18. Wiewel MA, van Vught LA, Scicluna BP, Hoogendijk AJ, Frencken JF, Zwinderman AH, Horn J, Cremer OL, Bonten MJ, Schultz MJ *et al.* Prior Use of Calcium Channel Blockers Is Associated With Decreased Mortality in Critically Ill Patients With Sepsis: A Prospective Observational Study. *CRIT CARE MED* 2017, 45(3):454-463.

19. Dial S, Nessim SJ, Kezouh A, Benisty J, Suissa S: Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis. *Br J Clin Pharmacol* 2014, 78(5):1151-1158.

20. Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A, Cornell JE, Pugh MJ: Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. *PHARMACOTHERAPY* 2007, 27(12):1619-1626.

21. Wang Y, Allen KJ, Suaini N, Peters RL, Ponsonby AL, Koplin JJ: Asian children living in Australia have a different profile of allergy and anaphylaxis than Australian-born children: A State-wide survey. *CLIN EXP ALLERGY* 2018, 48(10):1317-1324.

22. Turana Y, Tengkawan J, Soenarta AA: Asian management of hypertension: Current status, home blood pressure, and specific concerns in Indonesia. *J Clin Hypertens (Greenwich)* 2019.
23. Poon L, Yu CP, Peng L, Ewig CL, Zhang H, Li CK, Cheung YT: Clinical ascertainment of health outcomes in Asian survivors of childhood cancer: a systematic review. *J CANCER SURVIV* 2019, 13(3):374-396.

24. Snijder MB, Galenkamp H, Prins M, Derks EM, Peters R, Zwinderman AH, Stronks K: Cohort profile: the Healthy Life in an Urban Setting (HELIUS) study in Amsterdam, The Netherlands. *BMJ OPEN* 2017, 7(12):e17873.

25. Crowe R, Stanley R, Probst Y, McMahon A: Culture and healthy lifestyles: a qualitative exploration of the role of food and physical activity in three urban Australian Indigenous communities. *Aust N Z J Public Health* 2017, 41(4):411-416.

26. Vang ZM, Sigouin J, Flenon A, Gagnon A: Are immigrants healthier than native-born Canadians? A systematic review of the healthy immigrant effect in Canada. *Ethn Health* 2017, 22(3):209-241.

27. Williams GH: Converting-enzyme inhibitors in the treatment of hypertension. *N Engl J Med* 1988, 319(23):1517-1525.

28. Chen JY, Kang N, Juarez DT, Yermilov I, Braithwaite RS, Hodges KA, Legorreta A, Chung RS: Heart failure patients receiving ACEIs/ARBs were less likely to be hospitalized or to use emergency care in the following year. *J Healthc Qual* 2011, 33(4):29-36.

29. Brown T, Gonzalez J, Monteleone C: Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature. *J Clin Hypertens (Greenwich)* 2017, 19(12):1377-1382.

30. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Froland SS, Fowler M: Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. *J AM COLL CARDIOL* 1999, 34(7):2061-2067.

31. Hagiwara S, Iwasaka H, Hidaka S, Hasegawa A, Koga H, Noguchi T: Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats. *Intensive Care Med* 2009, 35(8):1471-1478.

32. Wan L, Langenberg C, Bellomo R, May CN: Angiotensin II in experimental hyperdynamic sepsis. *CRIT CARE* 2009, 13(6):R190.

33. Laesser M, Oi Y, Ewert S, Fandriks L, Aneman A: The angiotensin II receptor blocker candesartan improves survival and mesenteric perfusion in an acute porcine endotoxin model. *Acta Anaesthesiol Scand* 2004, 48(2):198-204.

34. Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A, Cornell JE, Pugh MJ: Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. *PHARMACOTHERAPY* 2007, 27(12):1619-1626.

35. ACEIs or ARBs For Adults With Hypertension: Clinician's Guide. 2007.

36. Ishigami T, Uchino K, Umemura S: ARBs or ACEIs, that is the question. *HYPERTENS RES* 2006, 29(11):837-838.

**Figures**
Figure 1

Records were identified through Pubmed and Embase, Web of Science, and Cochrane Library (n=103).

Additional records were identified through searching reference list (n=15).

Articles excluded by screen of titles or Abstracts (n=11);
Reviews or letters (n=9);
Endpoint not relevant (n=66);
NOS score <5 (n=1).

Full-text articles reviewed for more detailed evaluation (n=31).

Combined intervention (n=3);
Not report any of outcome (n=22).

Articles accepted for analysis (n=6).

Figure 1

Search strategy and selection of studies for inclusion in the meta-analysis.
Figure 2

Random-effects meta-analysis between premorbid ACEIs or ARBs exposure and mortality in patients with sepsis.
Figure 3

Sensitivity analysis of all included studies.
Figure 4

Meta-regulation of premorbid ACEIs or ARBs exposure and mortality in patients with sepsis.
Figure 5

Begg’s funnel plot assessing publication bias among the selected studies.
Figure 6

Egger's funnel plot assessing publication bias among the selected studies.